Benitec Biopharma (BNTC) Amortization of Deferred Charges (2019 - 2025)
Benitec Biopharma (BNTC) has disclosed Amortization of Deferred Charges for 7 consecutive years, with $104000.0 as the latest value for Q2 2025.
- Quarterly Amortization of Deferred Charges rose 60.0% to $104000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $330000.0 through Jun 2025, up 28.91% year-over-year, with the annual reading at $330000.0 for FY2025, 28.91% up from the prior year.
- Amortization of Deferred Charges hit $104000.0 in Q2 2025 for Benitec Biopharma, up from $93000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $104000.0 in Q2 2025 to a low of $48000.0 in Q1 2021.
- Historically, Amortization of Deferred Charges has averaged $64111.1 across 5 years, with a median of $62000.0 in 2022.
- Biggest five-year swings in Amortization of Deferred Charges: rose 1.67% in 2023 and later skyrocketed 60.0% in 2025.
- Year by year, Amortization of Deferred Charges stood at $58000.0 in 2021, then rose by 5.17% to $61000.0 in 2022, then increased by 3.28% to $63000.0 in 2023, then increased by 6.35% to $67000.0 in 2024, then skyrocketed by 55.22% to $104000.0 in 2025.
- Business Quant data shows Amortization of Deferred Charges for BNTC at $104000.0 in Q2 2025, $93000.0 in Q1 2025, and $67000.0 in Q4 2024.